Boehringer Ingelheim (BI), a leading German pharmaceutical company, has announced a research collaboration and license agreement with Circle Pharma, a US-based firm. This strategic partnership aims to develop a first-in-class cyclin inhibitor, a novel approach that could halt the growth of cancer cells and offer new hope for patients struggling with hard-to-treat cancers.
Traditional methods targeting cyclin-dependent kinases often face limitations due to low selectivity and potential toxicity. Circle Pharma has addressed these challenges by developing macrocycle therapies that directly inhibit cyclins, the proteins responsible for regulating cell division. Under the terms of the agreement, Boehringer Ingelheim will work in tandem with Circle Pharma’s scientists to develop innovative tumor therapies based on Circle’s proprietary MXMO platform. Circle Pharma is set to receive an upfront payment and is eligible for potential development, regulatory, and sales milestone payments that could total up to USD 607 million.- Flcube.com
